Você procurou por: antigenically (Inglês - Maltês)

antigenically matched strains
razez imqabbla b’mod antiġenetiku

optaflu efficacy was defined as the prevention of culture-confirmed symptomatic influenza illness caused by viruses antigenically matched to those in the vaccine compared to placebo.
l-effikaċja ta’ optaflu ġiet definita bħala l-prevenzjoni ta’ mard tal-influwenza sintomatiku kkonfermat mill-koltura, ikkawżat minn virusijiet li tqabblu b’mod antiġenetiku ma’ dawk fit-tilqima meta mqabbla mal-plaċebo.

a multi-strain dossier means a single dossier containing the relevant data for a unique and thorough scientific assessment of the different options of strains or combinations of strains permitting the authorisation of vaccines against antigenically variable viruses.
dossier dwarir-razez multipli jfisser dossier wieħed li jkollu d-dejta rilevanti għal valutazzjoni unika u sħiħa tad-diversi għażliet ta’ razez jew kumbinazzjoni ta' razez, li tippermetti l-awtorizzazzjoni ta’ vaċċini kontra vajrusis antiġenikalment varjabbli.

in previously unvaccinated study participants who received one dose in year 1, efficacy was 57.7% (95% ci: 44.7, 67.9) against matched strains and 56.3% (95% ci: 43.1, 66.7) against all strains regardless of match, respectively, thus supporting the need for two doses of vaccine in previously unvaccinated children. ein study participants who received 2 doses in year 1 and placebo in year 2, efficacy in year 2 was 56.2% (95% ci: 30.5, 72.7) against matched strains and 44.8% (95% ci: 18.2, 62.9) against all strains regardless of match, respectively, in d153-p501, thus supporting the need for second-season revaccination. fthe primary circulating strain was antigenically dissimilar from the h3n2 strain represented in the vaccine; efficacy against the mismatched a/h3n2 strain was 85.9% (95% ci: 75.3, 91.9).
fil-parteċipanti fl-istudju li qatt ma kienu tlaqqmu qabel li rċevew doża waħda fis-sena 1, l-effikaċja kienet ta’ 57.7% (95% ci: 44.7, 67.9) kontra r-razez li jaqblu u ta’ 56.3% (95% ci: 43.1, 66.7) kontra r-razez kollha irrispettivament mit-tqabbil, rispettivament, u dan jappoġġja l-ħtieġa għal żewġ dożi tat-tilqima fi tfal li ma kinux tlaqqmu qabel. ef’parteċipanti tal-istudji li rċevew 2 dożi fis-sena 1 u plaċebo fis-sena 2, l-effikaċja fis-sena 2 kienet ta’ 56.2% (95% ci: 30.5, 72.7) kontra r-razez li jaqblu u ta’ 44.8% (95% ci: 18.2, 62.9) kontra r-razez kollha irrispettivament minn jekk jaqblux, rispettivament, f’d153-p501, u dan jappoġġja l-ħtieġa għal rivaċċinazzjoni fit-tieni staġun. fir-razza primarja ċirkolanti kienet antiġenikament differenti mir-razza h3n2 rappreżentata fit-tilqima; l- effikaċja kontra r-razza a/h3n2 mhux imqabbla kienet ta’ 85.9% (95% ci: (75.3, 91.9)